

Cardiac Myosin Inhibitors in Obstructive Hypertrophic Cardiomyopathy in Contemporary Clinical Practice

This breakfast symposium will provide heart failure specialists and care providers insights into the recent guidelines for the management of obstructive hypertrophic cardiomyopathy (HCM) from the AHA/ACC and the European Society of Cardiology. Specifically, the appropriate and practical use of cardiac myosin inhibitors in clinical practice will be highlighted by a diverse group of HCM specialists.

AGENDA

- **Introduction**
- **Guideline update on the treatment of obstructive HCM**
- **Major findings from randomized trials of cardiac myosin inhibitors (CMIs)**
- **Real world use of CMI in clinical practice: What I've learned**
- **Key role of cardiac imaging in treatment selection**



Scan to register or visit
<https://hcmsociety.org/event-5809038/Registration>. Advance registration required

Faculty

**MILIND DESAI, MD, MBA,
FACC, FAHA, FESC**

Cleveland Clinic Lerner College of
Medicine, Cleveland, OH

CAROLYN HO, MD

Brigham and Women's Hospital
Boston, MA

MATTHEW MARTINEZ, MD

Atlantic Health System - Moristown
Medical Center, Morristown, NJ

ANJALI OWENS, MD

Hospital of the University of
Pennsylvania, Philadelphia, PA

**ANDREW WANG, MD, FACC,
FAHA**

Duke University School of Medicine,
Durham, NC

This Satellite Symposium is presented through a collaboration between HCM Society and the Heart Failure Society of America. The program topic, learning objectives, and faculty have been reviewed and approved by the ASM Satellite Review Committee. Satellite sessions are not a part of the scientific program as planned and executed by the HFSA Program Committee.